Last reviewed · How we verify
Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib
Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib is a PD-1 inhibitor Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently in Phase 3 development for Non-small cell lung cancer, Small cell lung cancer, Esophageal squamous cell carcinoma.
Tislelizumab is a PD-1 inhibitor that blocks the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells.
Tislelizumab is a PD-1 inhibitor that blocks the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells and thereby enhancing the immune response against cancer cells. Used for Non-small cell lung cancer, Small cell lung cancer, Esophageal squamous cell carcinoma.
At a glance
| Generic name | Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab works by binding to the PD-1 receptor on T cells, preventing the interaction with PD-L1 on tumor cells. This prevents the tumor cells from evading the immune response, allowing the T cells to attack and kill the cancer cells. The combination with cisplatin and gemcitabine, and trilaciclib, a CDK4/6 inhibitor, aims to enhance the anti-tumor effect.
Approved indications
- Non-small cell lung cancer
- Small cell lung cancer
- Esophageal squamous cell carcinoma
- Gastric or gastroesophageal junction adenocarcinoma
- Hepatocellular carcinoma
- Urothelial carcinoma
- Cervical cancer
- Malignant pleural mesothelioma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib CI brief — competitive landscape report
- Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib
What is Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib?
How does Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib work?
What is Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib used for?
Who makes Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib?
What drug class is Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib in?
What development phase is Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib in?
What are the side effects of Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib?
What does Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Esophageal squamous cell carcinoma
- Compare: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib vs similar drugs
- Pricing: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib cost, discount & access